Nathan Blue
( out of 16 reviews )

Nathan Blue, MD, MSCI

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000
Get Directions

University of Utah Hospital

University Maternal Fetal Medicine, Area E
50 N Medical Dr
Salt Lake City , UT 84132
801-213-2995
Get Directions

Greenwood Health Center

7495 South State Street
Midvale , UT 84047
801-213-9400
Get Directions

As a dedicated and compassionate provider, Dr. Nathan Blue is a high-risk pregnancy specialist. Dr. Blue has a clinical interest in preeclampsia/hypertension in pregnancy, fetal growth restriction, stillbirth, and complications related to maternal and fetal health. For all his patients, he provides comprehensive prenatal care for individuals with complex pregnancies.

Dr. Blue is currently accepting new patients. To make an appointment, please call the Women’s Health Center at 801-213-2995 for more information.

Dr. Blue earned his medical degree from Loma Linda University School of Medicine in California. He completed his Obstetrics & Gynecology residency at Los Angeles General Medical Center, where he developed a strong passion for research and a commitment to serving underserved patients. Following this, he pursued a fellowship at the University of New Mexico and served as a Women's Reproductive Health Research (WRHR) K12 scholar at University of Utah Health from 2018 to 2022.

His ongoing NIH-funded research aims to use AI to create personalized prenatal risk assessment tools, helping families and health care providers make informed decisions in uncertain situations. Dr. Blue has researched critical topics such as preeclampsia, preterm birth, stillbirth, and fetal growth restriction.

As a fluent Spanish speaker, Dr. Blue enjoys working with the Spanish-speaking communities.

Specialties

Board Certification

American Board of Obstetrics & Gynecology
American Board of Obstetrics & Gynecology (Sub: Maternal-Fetal Medicine)

Patient Rating

4.9 /5
( out of 16 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

SUGAR HOUSE HEALTH CENTER

One of the best doctors I've ever had. Extremely intelligent, amazing bedside manner. Gives me all the medical information I need to make the best decision for me and my health, and then genuinely and fully supports the decision he's empowered me to make for my body.

SUGAR HOUSE HEALTH CENTER

Very approachable physician, great bedside manner. He shakes hands at the beginning and end of appointments which I like. He spends a lot of time with patients. The wait can be long, but it's because he spends a lot of time with patients.

SUGAR HOUSE HEALTH CENTER

I was surprised and appreciative that Dr. Blue was willing to take so much time with me to thoroughly answer questions during my first visit.

SUGAR HOUSE HEALTH CENTER

Dr. Blue always includes me like I'm part of the care team. I feel that he respects where I'm coming from, and always takes the time to answer my questions and explain my options. I couldn't imagine a better doc for me during this wild ride.

SUGAR HOUSE HEALTH CENTER

Excellent treatment from Dr. Blue. On top of offering his expert opinion on pregnancy matters, he offered pretty solid psychological counseling. Very good at listening and validating my emotions.

SUGAR HOUSE HEALTH CENTER

Dr. Blue is caring, attentive, and easygoing all in one. We have a high risk pregnancy and he listens to and addresses our concerns, answers ALL questions no matter how big or small, and takes care to explain/weigh options with us.

SUGAR HOUSE HEALTH CENTER

Dr. Blue is always inquisitive about my experience and welcomes questions. He has been very thorough in explaining my condition and I really like his approach, it's very comprehensive.

SUGAR HOUSE HEALTH CENTER

Dr.Blue is very engaged in my treatment. He is intelligent and listens to my concerns then makes a plan with me.

SUGAR HOUSE HEALTH CENTER

Dr. Blue is awesome! It was worth the wait to get to chat with him. Very knowledgeable and you can tell he really enjoys the work he does. I learned a lot with just one appointment with him. He is down to earth and very approachable. I'd definitely recommend him to friends and family.

As a dedicated and compassionate provider, Dr. Nathan Blue is a high-risk pregnancy specialist. Dr. Blue has a clinical interest in preeclampsia/hypertension in pregnancy, fetal growth restriction, stillbirth, and complications related to maternal and fetal health. For all his patients, he provides comprehensive prenatal care for individuals with complex pregnancies.

Dr. Blue is currently accepting new patients. To make an appointment, please call the Women’s Health Center at 801-213-2995 for more information.

Dr. Blue earned his medical degree from Loma Linda University School of Medicine in California. He completed his Obstetrics & Gynecology residency at Los Angeles General Medical Center, where he developed a strong passion for research and a commitment to serving underserved patients. Following this, he pursued a fellowship at the University of New Mexico and served as a Women's Reproductive Health Research (WRHR) K12 scholar at University of Utah Health from 2018 to 2022.

His ongoing NIH-funded research aims to use AI to create personalized prenatal risk assessment tools, helping families and health care providers make informed decisions in uncertain situations. Dr. Blue has researched critical topics such as preeclampsia, preterm birth, stillbirth, and fetal growth restriction.

As a fluent Spanish speaker, Dr. Blue enjoys working with the Spanish-speaking communities.

Board Certification and Academic Information

Academic Departments Obstetrics & Gynecology -Associate Professor (Clinical)
Population Health Sciences -Adjunct Assistant Professor
Academic Divisions Maternal Fetal Medicine
Board Certification
American Board of Obstetrics & Gynecology
American Board of Obstetrics & Gynecology (Sub: Maternal-Fetal Medicine)

Education history

Undergraduate Spanish - Pacific Union College B.A.
Professional Medical Medicine - Loma Linda University School of Medicine M.D.
Residency Obstetrics and Gynecology - Los Angeles County + USC Medical Center Resident
Fellowship Maternal-Fetal Medicine - University of New Mexico School of Medicine Fellow
Diploma University of Utah M.S.C.I

Selected Publications

Journal Article

  1. Blue NR, Murray-Krezan C, Drake-Lavelle S, Weinberg D, Holbrook BD, Katukuri VR, Leeman L, Mozurkewich EL (2018). Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. Am J Obstet Gynecol, 218(6), 616.e1-616.e8.
  2. Blue NR, Beddow ME, Savabi M, Katukuri VR, Chao CR (2018). Comparing the Hadlock fetal growth standard to the Eunice Kennedy Shriver National Institute of Child Health and Human Development racial/ethnic standard for the prediction of neonatal morbidity and small for gestational age. Am J Obstet Gynecol, 219(5), 474.e1-474.e12.
  3. Blue NR, Van Winden KR, Pathak B, Barton L, Opper N, Lane CJ, Ramanathan R, Ouzounian JG, Lee R (2015). Neonatal Outcomes by Mode of Delivery in Preterm Birth. American journal of perinatology, 32(14), 1292-7.
  4. Blue NR, Yordan JMP, Holbrook BD, Nirgudkar PA, Mozurkewich E (2017). Abdominal Circumference Alone versus Estimated Fetal Weight after 24 Weeks to Predict Small or Large for Gestational Age at Birth: A Meta-Analysis. American journal of perinatology, 34(11), 1115-1124.
  5. Blue NR, Hoffman M, Allshouse AA, Grobman WA, Simhan HN, Turan OM, Parry S, Chung JH, Reddy U, Haas DM, Myers S, Mercer B, Saade GR, Silver R (2021). Antenatal Fetal Adrenal Measurements at 22 to 30 Weeks' Gestation, Fetal Growth Restriction, and Perinatal Morbidity. American journal of perinatology, 38(7), 676-682.
  6. Blue NR, Grobman WA, Larkin JC, Scifres CM, Simhan HN, Chung JH, Saade GR, Haas DM, Wapner R, Reddy UM, Mercer B, Parry SI, Silver R (2021). Customized versus Population Growth Standards for Morbidity and Mortality Risk Stratification Using Ultrasonographic Fetal Growth Assessment at 22 to 29 Weeks' Gestation. American journal of perinatology, 38(S 01), e46-e56.
  7. Bruno AM, Shea AE, Einerson BD, Metz TD, Allshouse AA, Scott JR, Blue N (2021). Impact of the p-Value Threshold on Interpretation of Trial Outcomes in Obstetrics and Gynecology. American journal of perinatology, 38(12), 1223-1230.
  8. Blue NR, Savabi M, Beddow ME, Katukuri VR, Fritts CM, Izquierdo LA, Chao C (2019). The Hadlock Method Is Superior to Newer Methods for the Prediction of the Birth Weight Percentile. Journal of ultrasound in medicine, 38(3), 587-596.
  9. Blue NR, Beddow ME, Savabi M, Katukuri VR, Mozurkewich EL, Chao C (2018). A Comparison of Methods for the Diagnosis of Fetal Growth Restriction Between the Royal College of Obstetricians and Gynaecologists and the American College of Obstetricians and Gynecologists. Obstetrics and gynecology, 131(5), 835-841.
  10. Hammad IA, Blue NR, Allshouse AA, Silver RM, Gibbins KJ, Page JM, Goldenberg RL, Reddy UM, Saade GR, Dudley DJ, Thorsten VR, Conway DL, Pinar H, Pysher TJ, NICHD Stillbirth Collaborative Research Network Group (2020). Umbilical Cord Abnormalities and Stillbirth. Obstetrics and gynecology, 135(3), 644-652.
  11. Blue NR, Page JM, Silver R (2021). Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. Obstetrics and gynecology clinics of North America, 48(2), 419-436.
  12. Page JM, Blue NR, Silver R (2021). Fetal Growth and Stillbirth. Obstetrics and gynecology clinics of North America, 48(2), 297-310.
  13. Blue NR, Page JM, Silver R (2019). Genetic abnormalities and pregnancy loss. Seminars in perinatology, 43(2), 66-73.
  14. Hawkins M, Parker CB, Redline S, Larkin JC, Zee PP, Grobman WA, Silver RM, Louis JM, Pien GW, Basner RC, Chung JH, Haas DM, Nhan-Chang CL, Simhan HN, Blue NR, Parry S, Reddy U, Facco F, NICHD NuMoM2b and NHLBI NuMoM2b Heart Health Study Networks (2021). Objectively assessed sleep-disordered breathing during pregnancy and infant birthweight. Sleep medicine, 81, 312-318.
  15. Bruno AM, Blue NR, Allshouse AA, Haas DM, Shanks AL, Grobman WA, Simhan H, Reddy UM, Silver RM, Metz T (2021). Marijuana use, fetal growth, and uterine artery Dopplers. The journal of maternal-fetal & neonatal medicine, 35, 1-8.
  16. Blue NR, Allshouse AA, Grobman WA, Day RC, Haas DM, Simhan HN, Parry S, Saade GR, Silver R (2021). Developing a predictive model for perinatal morbidity among small for gestational age infants. The journal of maternal-fetal & neonatal medicine, 35, 1-10.
  17. Gimbel LA, Blue NR, Allshouse AA, Silver RM, Gimbel B, Grobman WA, Haas DM, Simhan HN, Mercer BM, Hatfield (2021). Pregnancy outcomes and anxiety in nulliparous women. The journal of maternal-fetal & neonatal medicine, 35, 1-10.
  18. Bruno AM, Olmsted MW, Martin V, Einerson BD, Metz TD, Allshouse AA, Scott JR, Blue N (2021). Rigor, reproducibility, and transparency of randomized controlled trials in obstetrics and gynecology. American journal of obstetrics & gynecology MFM, 3(6), 100450.
  19. Lueth A, Blue N, Silver RM, Allshouse A, Hoffman M, Grobman WA, Simhan HN, Reddy U, Haas D (2021). Prospective evaluation of placental abruption in nulliparous women. The journal of maternal-fetal & neonatal medicine, 35, 1-8.
  20. Blue NR, Mele L, Grobman WA, Bailit JL, Wapner RJ, Thorp JM Jr, Caritis SN, Prasad M, Tita ATN, Saade GR, Rouse DJ, Blackwell SC, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network(#) (2022). Predictive Performance of Newborn Small for Gestational Age by a U.S. Intrauterine versus Birth Weight-derived Standard for Short-Term Neonatal Morbidity and Mortality. American journal of obstetrics & gynecology MFM, 4, 100599.
  21. Beck MC, Allshouse MA, Silver RM, Grobman WA, Simhan H, Haas D, Reddy UM, Blue N (2022). High early pregnancy body mass index is associated with alterations in first and second trimester angiogenic biomarkers. American journal of obstetrics & gynecology MFM, 4, 100614.
  22. Bruno AM, Blue N (2022). Challenges in Interpreting Obstetrics and Gynecology Literature. Clinical obstetrics and gynecology, 65, 225-235.
  23. Carey AZ, Blue NR, Varner MW, Page JM, Chaiyakunapruk N, Quinlan AR, Branch DW, Silver RM, Workalemahu (2021). A systematic review to guide future efforts in the determination of genetic causes of pregnancy loss. Frontiers in reproductive health, 3,
  24. Blue NR, Allshouse AA, Heerboth S, Grobman W, Mercer B, Shanks A, Bregand-White JM, Simhan H, Reddy UM, Saade G, Parry S, Silver R (2022). Derivation and assessment of a sex-specific fetal growth standard. The journal of maternal-fetal & neonatal medicine, 35(25), 1-9.
  25. Bruno A, Benson AE, Metz T, Blue N (2022). Adjunct therapy at time of exam-indicated cervical cerclage in singleton pregnancies: a systematic review and meta-analysis. American journal of perinatology, 39(16), 1719-1725.
  26. Bridges AG, Allshouse A, Canfield DR, Grover BW, Son SL, Einerson BD, Silver RM, Haas D, Grobman W, Simhan H, Day RC, Blue N (2022). Association of Prostaglandin Use for Cervical Ripening with Mode of Delivery in SGA vs non-SGA Neonates. American journal of perinatology,
  27. Schabel MC, Roberts VHJ, Gibbins KJ, Rincon M, Gaffney JE, Streblow AD, Wright AM, Lo JO, Park B, Kroenke CD, Szczotka K, Blue NR, Page JM, Harvey K, Varner MW, Silver RM, Frias A (2022). Quantitative longitudinal T2* mapping for assessing placental function and association with adverse pregnancy outcomes across gestation. PloS one, 17(7), e0270360.
  28. Workalemahu T, Dalton S, Allshouse A, Carey AZ, Page JM, Blue NR, Thorsten V, Goldenberg RL, Pinar H, Reddy UM, Silver R (2022). Copy number variants and placental abnormalities in stillborn fetuses: a secondary analysis of the Stillbirth Collaborative Research Network study. BJOG, 129(13), 2125-2131.
  29. Lueth AJ, Allshouse AA, Blue NR, Grobman WA, Levine LD, Simhan HN, Kim JK, Johnson J, Wilson FA, Murtaugh M, Silver RM, for the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b), and National Heart, Lung, and Blood Institute (NHLBI) nuMoM2b Heart Health Study (nuMoM2b-HHS (2022). Allostatic Load and Adverse Pregnancy Outcomes. Obstetrics and gynecology, 140(6), 974-982.
  30. Workalemahu T, Avery C, Lopez S, Blue NR, Wallace A, Quinlan AR, Coon H, Warner D, Varner MW, Branch DW, Jorde LB, Silver R (2023). Whole-genome sequencing analysis in families with recurrent pregnancy loss: A pilot study. PloS one, 18(2), e0281934.
  31. Li X, Quick C, Zhou H, [and 421 others, including Blue NR for the NHLBI Trans-Omics for Precision Medicine Consortium (2022). Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies. Nature genetics,
  32. Rayburn WF,Smith GA,Blue (2019). Fetal ultrasound interpretation using a flipped learning approach during an introductory obstetrics clerkship. The Journal of reproductive medicine, 64(2), 151-153.
  33. Weinberg D,Blue N,Holbrook B,Rayburn (2017). Outpatient preinduction cervical ripening using a balloon catheter: A meta-analysis. The Journal of reproductive medicine, 62(5), 486-492.
  34. Li, Z., Li, X., Zhou, H. et al [and 498 others, including Blue NR for the Trans-Omics for Precision Medicine (TOPMed) Consortium] (2022). A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies. Nature methods, 19, 1599¿1611.
  35. Lueth AJ, Allshouse AA, Blue NM, Grobman WA, Levine LD, Catov J, Saade G, Yee LM, Wilson FA, Murtaugh M, Merz N, Chung J, Ray M, Scifres C, Silver RM, NIH NICHD nuMoM2b and NHLBI nuMoM2b Heart Health Study Network (2023). Can allostatic load in pregnancy explain the association between race and subsequent cardiovascular disease risk: A cohort study. BJOG, 130(10), 1197-1206.
  36. Workalemahu T, Dalton S, Son SL, Allshouse A, Carey AZ, Page JM, Blue NR, Thorsten V, Goldenberg RL, Pinar H, Reddy UM, Silver R (2023). Copy number variants and fetal structural abnormalities in stillborn fetuses: A secondary analysis of the Stillbirth Collaborative Research Network study. BJOG, 131(2), 157-162.
  37. Zimmerman RM, Hernandez EJ, Watkins WS, Blue N, Tristani-Firouzi M, Yandell M, Steinberg B (2023). An Explainable Artificial Intelligence Approach for Discovering Social Determinants of Health and Risk Interactions for Stroke in Patients With Atrial Fibrillation. The American journal of cardiology, 201, 224-226.
  38. Yan Q, Guerrero RF, Khan RR, Surujnarine AA, Wapner RJ, Hahn MW, Raja A, Salleb-Aouissi A, Grobman WA, Simhan H, Blue NR, Silver R, Chung JH, Reddy UM, Radivojac P, Pe'er I, Haas D (2023). Searching and visualizing genetic associations of pregnancy traits by using GnuMoM2b. Genetics, 225(2),
  39. Gleason JL, Reddy UM, Chen Z, Grobman WA, Wapner RJ, Steller JG, Simhan H, Scifres CM, Blue N, Parry S, Grantz K (2023). Comparing population-based fetal growth standards in a US cohort. American journal of obstetrics and gynecology,
  40. Finch A, Joss-Moore L, Allshouse A, Blue N, Haas D, Grobman WA, Parry S, Saade G, Silver R (2024). Maternal Pre-Conception Omega-6, Omega-3, and Omega-6:Omega-3 Intake and Uterine Artery Indices in Mid-Gestation. American journal of perinatology,
  41. Wallace AD, Blue NR, Morgan T, Workalemahu T, Silver RM, Quinlan A (2024). Placental somatic mutation in human stillbirth and live birth: A pilot case-control study of paired placental, fetal, and maternal whole genomes. Placenta, 154, 137-144.
  42. Blue NR, Allshouse AA, Moyle KA, Dimick K, Silver R (2024). A Pilot Study of Ultrasound Assessment of Umbilical Cord and Placental Vascular Flow for Cord Accident Stillbirth Prevention. Journal of ultrasound in medicine,
  43. Beck C, Blue NR, Silver RM, Na M, Grobman WA, Steller J, Parry S, Scifres C, Gernand A (2024). Maternal vitamin D status, fetal growth patterns, and adverse pregnancy outcomes in a multi-site prospective pregnancy cohort. The American journal of clinical nutrition,
  44. Riches NO, Workalemahu T, Johnson EP, Lopez S, Blue N, Page J, Silver RM, Rothwell (2024). Factors Contributing to Uptake of Stillbirth Evaluations: A Qualitative Analysis. BJOG, 132(5), 606-613.
  45. Watkins WS, Hernandez EJ, Miller T, Blue N, Zimmerman R, Griffiths E, Frise E, Bernstein D, Boskovski M, Brueckner M, Chung W, Gaynor JW, Gelb B, Goldmuntz E, Gruber P, Newburger J, Roberts A, Morton S, Mayer J, Seidman C, Seidman J, Shen Y, Wagner M, Yost HJ, Yandell M, Tristani-Firouzi (2024). Genome Sequencing is Critical for Forecasting Outcomes Following Congenital Cardiac Surgery. In Press, Nature Communications. Nature communications,
  46. Zimmerman RM, Hernandez EJ, Yandell M, Tristani-Firouzi M, Silver RM, Grobman W, Haas D, Saade G, Steller J, Blue N (2024). AI-based analysis of fetal growth restriction in a prospective obstetric cohort quantifies compound risks for perinatal morbidity and mortality and identifies previously unrecognized high risk clinical scenarios. Research square,
  47. Yan Q, Guerrero RF, Khan RR, Surujnarine AA, Wapner RJ, Hahn MW, Raja A, SallebAouissi A, Grobman WA, Simhan H, Blue NR, Silver R, Chung JH, Reddy UM, Radivojac P, Pe'er I, Haas D (2023). Searching and visualizing genetic associations of pregnancy traits by using GnuMoM2b.
  48. Yan Q, Blue NR, Truong B, Zhang Y, Guerrero RF, Liu N, Honigberg MC, Parry S, McNeil RB, Simhan HN, Chung J, Mercer BM, Grobman WA, Silver R, Greenland P, Saade GR, Reddy UM, Wapner RJ, Haas D (2024). Genetic Associations with Placental Proteins in Maternal Serum Identify Biomarkers for Hypertension in Pregnancy.
  49. Zimmerman RM, Hernandez EJ, Yandell M, Tristani-Firouzi M, Silver RM, Grobman W, Haas D, Saade G, Steller J, Blue N (2025). AI-based analysis of fetal growth restriction in a prospective obstetric cohort quantifies compound risks for perinatal morbidity and mortality and identifies previously unrecognized high risk clinical scenarios. BMC pregnancy and childbirth, 25(1), 80.
  50. Watkins WS, Hernandez EJ, Miller TA, Blue NR, Zimmerman RM, Griffiths ER, Frise E, Bernstein D, Boskovski MT, Brueckner M, Chung WK, Gaynor JW, Gelb BD, Goldmuntz E, Gruber PJ, Newburger JW, Roberts AE, Morton SU, Mayer JE Jr, Seidman CE, Seidman JG, Shen Y, Wagner M, Yost HJ, Yandell M, Tristani-Firouzi (2025). Genome sequencing is critical for forecasting outcomes following congenital cardiac surgery. Nature communications, 16(1), 6365.
  51. Post SE, Blue N (2025). Predicting Perinatal Morbidity in Fetal Growth Restriction: Evidence, Challenges, and Opportunities. Clinical obstetrics and gynecology,
  52. Joseph M, Pappas L, Guerrero R, Zeinomar M, Mims JR Jr, Moore B, Workalemahu T, Scifres C, Steller JG, Saade G, Silver RM, Blue N (2025). Use of a Maternal Genetic Risk Score to Derive and Test a Genetically Customized Fetal Growth Curve. O&G open, 2(5), e110.
  53. Yan Q, Zhang Y, Blue NR, Truong B, Guerrero RF, Honigberg MC, Parry S, McNeil RB, Simhan HN, Chung J, Mercer BM, Grobman WA, Silver R, Greenland P, Saade GR, Reddy UM, Wapner RJ, Liu N, Haas D (2025). Genetic Associations with Placental and Pregnancy Proteins in Maternal Serum Identify Biomarkers for Hypertension in Pregnancy. American journal of obstetrics and gynecology,
  54. Workalemahu T, Madsen MJ, Lopez S, Page JM, Blue NR, Avery C, Sargent R, Yu Z, Guinto E, Branch DW, Leisher S, Jorde LB, Quinlan A, Coon H, Varner MW, Roberts CT, Neklason DW, Camp NJ, Silver R (2025). Inherited Genetic Risk in Stillbirth: A Shared Genomic Segments Analysis of High-Risk Pedigrees. HGG advances, 7(1), 100546.
  55. Tristani-Firouzi B, Pappas L, Joseph M, Zeinomar M, Debbink MP, Mims J, Guerrero R, Moore B, Silver RM, Workalemahu T, Haas D, Steller JG, Saade G, Blue N (2025). Generalisability of Maternal Genetic Risk Score for Birth Weight Across Racial Identity and Ancestry: A Secondary Analysis of a Prospective Cohort Study. BJOG,
  56. Diener M, Din S, Sharma J, Stark LA, Metz TD, Knight SJ, Hansen L, Chavez A, Redding T, Blue N, Park A (2025). Prenatal Education to Support Pregnant People's Awareness, Knowledge, and Reported Oral Exposure and Risk Reduction Behaviors Surrounding Congenital Cytomegalovirus. Women's health issues,

Review

  1. Doyle AA, Blue N (2026). Stillbirth Prediction: Current Approaches, Challenges, and Future Directions. Clinics in perinatology, 53(1), 119-133.

Editorial

  1. Silver RM, Blue N (2021). Delivery Before 39 Weeks' Gestation for Suspected Fetal Growth Restriction: More Harm Than Good?. JAMA, 326(2), 135-136.
  2. Blue NR, Silver R (2021). Fetal Growth in the Twenty-First Century: A Pressing Challenge for Clinicians and Researchers. Obstetrics and gynecology clinics of North America, 48(2), xvii-xviii.

News & Podcasts

News